Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.68 |
| ▸ | TSHR | P16473 | 2/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.63 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.63 |
| ▸ | RAB9A | P51151 | 1/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.63 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10041806 | 0.85 | LMNA (0.45) | LMNAHSD17B10TSHRCYP3A4NFKB1 | |
| SCHEMBL10041800 | 0.83 | LMNA (0.68) | LMNAHSD17B10TSHRCYP3A4NFKB1 | |
| Tybamate SCHEMBL78046 | 0.82 | LMNA (0.68) | LMNAHSD17B10TSHRCYP3A4NFKB1 | |
| Meprobamate SCHEMBL20545451 | 0.82 | LMNA (0.92) | LMNAHSD17B10TSHRCYP3A4NFKB1 | |
| Meprobamate SCHEMBL3056097 | 0.82 | LMNA (1.00) | LMNAHSD17B10TSHRCYP3A4NFKB1 | |
| Meprobamate SCHEMBL15286 | 0.82 | LMNA (1.00) | LMNAHSD17B10TSHRCYP3A4NFKB1 | |
| Meprobamate SCHEMBL18703920 | 0.81 | LMNA (0.96) | LMNAHSD17B10TSHRCYP3A4NFKB1 | |
| Meprobamate SCHEMBL8913202 | 0.81 | LMNA (0.96) | LMNAHSD17B10TSHRCYP3A4NFKB1 | |
| Meprobamate SCHEMBL7583576 | 0.81 | LMNA (0.96) | LMNAHSD17B10TSHRCYP3A4NFKB1 | |
| Meprobamate SCHEMBL29045066 | 0.81 | LMNA (0.96) | LMNAHSD17B10TSHRCYP3A4NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2418492-B1 | Immunoreagent for meprobamate | RANDOX LABORATORIES LTD (GB) | 2018-10-10 | — | — | EP | disclosed |
| US-20120040378-A1 | Meprobromate Immunoassay | RANDOX LABORATORIES LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| US-20120040378-A1 | Meprobromate Immunoassay | RANDOX LABORATORIES LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| EP-2418492-A1 | Meprobamate immunoassay | Randox Laboratories Ltd. (GB) | 2012-02-15 | — | — | EP | disclosed |
| EP-2418492-A1 | Meprobamate immunoassay | Randox Laboratories Ltd. (GB) | 2012-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040378-A1 | Meprobromate Immunoassay | MEP1B, CES2, MEP1A | LMNA 4619/4885HSD17B10 449/4885TSHR 740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.